Vancomycin HCl

• CAT Number: A000291
• CAS Number: 1404-93-9
• Molecular Formula: C66H75Cl2N9O24 • XHCl
• Molecular Weight: 1485.72
• Purity: ≥95%
• Target: Autophagy
• Solubility: Limited solubility
• Storage: 3 years -20C powder
• IUPAC Name: (1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid;hydrochloride
• InChI: InChI=1S/C66H75Cl2N9O24.ClH/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92;/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95);1H/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-;/m0./s1
• InChIKey: LCTORFDMHNKUSG-XTTLPDOESA-N
• SMILES: C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O.Cl

Vancomycin HCl（Cat No.:A000291）is a potent glycopeptide antibiotic primarily used to treat serious gram-positive bacterial infections, especially those caused by Staphylococcus aureus and Enterococcus species, including methicillin-resistant Staphylococcus aureus (MRSA). It works by inhibiting cell wall synthesis, which is essential for bacterial growth and survival. Often administered intravenously, Vancomycin HCl is reserved for severe infections such as septicemia, endocarditis, and complicated skin and soft tissue infections. Its efficacy against resistant strains and critical infections makes it an essential antibiotic in hospital settings, particularly for patients with limited treatment options.

Reference

Courvalin, Patrice. /Vancomycin Resistance in Gram-Positive Cocci./ Oxford Journals(2006): 25-34. Clinical Infectious Diseaes. Web. 21 Aug. 2012.Pollock, H.M., Holt J., and Murray C., Comparison of susceptibilities of anaerobic bacteria to cefemenoxime, ceftriaxone and other antimicrobial compounds, Antimicrob. Agents Chemother., Vol. 23, pp.780-783, 1983Silva J.A. and Fukai S., The impact of carbenicillin, cefotaxime and vancomycin on chrysanthemum and tobacco TCL morphogenesis and Agrobacterium growth, J. Appl. Hort., Vol. 3(1), pp. 3-12, 2001.Joshi, S., Ray, P., Manchanda, V., Bajaj, J., Chitnis, D. S., Gautam, V., &…Balaji, V. (2013). Methicillin resistant Staphylococcus aureus (MRSA) in India: Prevalence & susceptibility pattern. Indian Journal Of Medical Research, 137(2), 363-369